CGON today
$71.26-$1.35 (-1.86%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bearish
1 hourSymmetric Triangle
15 minBearish
5 minSymmetric Triangle
Daily trend turns up above $65.18
Key levels
Resistance$80.63
Resistance$73.16
Support$65.74
Support$59.22
Latest news & SEC filings
AnalystAnalyst firm lifts its target price on CG Oncology
AnalystCG Oncology Keeps Buy Rating From Guggenheim
AnalystGuggenheim keeps Buy rating on CG Oncology, cuts price target to $89
All CGON news →About CG Oncology
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. Its lead program targets earlier-stage bladder tumors that have not invaded muscle, including cases that no longer respond to BCG therapy. The company is also testing the therapy alongside other agents and preparing to commercialize it in the United States if approved.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
CG Oncology, Inc. (CGON)
What Is the Price Target for CGON?
SEPT Low Target
$79.00
SEPT Mid Target
$85.00
SEPT High Target
$100.00
Analyst Consensus
$85.00
Is CGON a Buy or Sell Right Now?
Thesis
- •Revenue growing 254.7% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CGON.
Start Free Trial →Is CGON Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$70.84
25
Moat Score
NONE
2/9
Piotroski Score
80.2
Altman Z-Score
What Is Smart Money Doing with CGON?
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| POST LEONARD E | director | Buy | 1,000 | $600.00 | Oct 15, 2026 |
| POST LEONARD E | director | Sale | 500 | $31K | Oct 15, 2026 |
| POST LEONARD E | director | Buy | 1,000 | $600.00 | Sep 15, 2026 |
| POST LEONARD E | director | Sale | 1,000 | $73K | Sep 15, 2026 |
| POST LEONARD E | director | Buy | 1,000 | $600.00 | Jun 4, 2026 |
| POST LEONARD E | director | Sale | 1,000 | $55K | Jun 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CGON Growth Story
Revenue YoY
254.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-47.52%
FCF Growth YoY
-67.8%
Revenue Trend
STRONG
Dark Pool Trades for CGON
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CGON, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:08 | $72.61 | 1,500 | $$109K | SELL |
| 21:00:08 | $72.61 | 1,510 | $$110K | SELL |
| 18:31:23 | $73.77 | 1,023 | $$75K | SELL |
| 18:31:06 | $73.38 | 13,400 | $$983K | SELL |
| 17:33:00 | $73.24 | 1,800 | $$132K | SELL |
5 dark pool trades shown · $$1.4M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CGON
PREVIEWSEPT Investing provides real-time options flow tracking for CGON, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $90 | Dec 18 | 37 | $$164.0K | 200 | BLOCK |
| CALL | $90 | Dec 18 | 37 | $$3520 | 4 | SWEEP |
| PUT | $70 | Nov 20 | 9 | $$31.6K | 34 | SWEEP |
| PUT | $70 | Nov 20 | 9 | $$4650 | 5 | SWEEP |
| PUT | $70 | Nov 20 | 9 | $$6510 | 7 | SWEEP |
5 options trades shown · 40% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for CG Oncology, Inc. (CGON) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CGON — frequently asked questions
What is CGON stock price today?
CG Oncology, Inc. (CGON) is at $71.26, down 1.86% (-$1.35) at the Nov 12, 2026 close.
Why is CGON stock moving today?
Latest CGON news — Nov 9, 2026: Analyst firm lifts its target price on CG Oncology · Nov 9, 2026: CG Oncology Keeps Buy Rating From Guggenheim
Why did CGON stock move on Nov 6, 2026?
CG Oncology shares surged 14.29% to close at $75.99 after the company reported third-quarter results that beat expectations. The company posted a loss of $0.64 per share, narrower than the $0.82 loss analysts projected, while revenue of $1.604 million topped the $643,584 estimate.
What is the CGON price target?
The average analyst price target for CGON is $85.00, ranging from $79 to $100, based on 7 analysts. Latest: Truist Securities maintains on Aug 7, 2026.
What do analysts rate CGON?
Analyst ratings for CGON: 0 Buy, 12 Hold, 0 Sell — consensus Hold.
Did CGON beat earnings?
CGON last reported on Nov 6, 2026: EPS -$0.64 vs -$0.83 expected — a beat of 23.3%.
Does CGON pay a dividend?
CGON does not currently pay a dividend.
What are CGON support and resistance levels?
Support: $65.74, $59.22, $53.21. Resistance: $73.16, $80.63.
What are insiders doing with CGON?
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
What is the latest news on CGON?
Nov 9, 2026: Analyst firm lifts its target price on CG Oncology · Nov 9, 2026: CG Oncology Keeps Buy Rating From Guggenheim · Nov 9, 2026: Guggenheim keeps Buy rating on CG Oncology, cuts price target to $89